Acute coronary syndromes: consensus recommendations  for translating knowledge into action

Brieger, David B; Chew, Derek; Aroney, Constantine; Aylward, Phil; Walters, Darren; Kelly, Anne-Maree; Boyden, Andrew

doi:10.5694/j.1326-5377.2010.tb04046.x

Topics

Cardiovascular diseases

In reply: We thank Forge for his continued and welcome contribution to this debate.

1 Coronary Care and Coronary Interventions, Concord Repatriation General Hospital, Sydney, NSW.
2 Southern Adelaide Health Service, Adelaide, SA.
3 Holy Spirit Northside Private Hospital, Brisbane, QLD.
4 Flinders Medical Centre, Adelaide, SA.
5 Prince Charles Hospital, Brisbane, QLD.
6 Joseph Epstein Centre for Emergency Medicine Research, Western Health, Melbourne, VIC.
7 National Heart Foundation of Australia, Canberra, ACT.

Correspondence: davidb@email.cs.nsw.gov.au

Competing interests:

The authors are all members of the NHFA ACS Guideline Implementation and Advocacy Working Group. David Brieger has been a member of advisory boards for Sanofi-Aventis, Eli Lilly, AstraZeneca and Boehringer Ingelheim, and has received research grants from Sanofi-Aventis, Eli Lilly, Schering-Plough and Merck Sharp & Dohme. Derek Chew has been a board member for Sanofi-Aventis, Eli Lilly and AstraZeneca, and has received reimbursement for travel/accommodation expenses from AstraZeneca and fees for expert testimony from Sanofi-Aventis and Eli Lilly. Constantine Aroney has received reimbursement for travel/accommodation expenses from Sanofi-Aventis, Eli Lilly and Medtronic and payment for developing educational presentations from Eli Lilly, Pfizer and The Medicines Company. Darren Walters has received a research fellowship from Medtronic and reimbursement of travel/accommodation expenses from Eli Lilly, AstraZeneca, Medtronic, GlaxoSmithKline, Johnson and Johnson, Universal Biosensors, Boston Scientific and Abbott Australasia, as well as organisations including the American Heart Association, the Royal Australasian College of Physicians and CSANZ. Philip Aylward has received research honoraria, speaker fees or travel assistance from TIMI Group (Harvard University), VIGOUR Group (Duke University), Pfizer, AstraZeneca, Eli Lilly, Boehringer Ingelheim and Sanofi-Aventis, and is a member of advisory boards to AstraZeneca, Sanofi-Aventis, Eli Lilly, CSL, Boehringer Ingelheim, and Pfizer. Anne-Maree Kelly has been on advisory boards for Sanofi-Aventis, AstraZeneca and Medical Developments International, and has received reimbursement for travel/accommodation expenses from Radiometer.

1. Hoenig MR, Aroney CN, Scott IA. Early invasive versus conservative strategies for unstable angina and non-ST elevation myocardial infarction in the stent era. Cochrane Database Syst Rev 2010; (3): CD004815.
2. O’Connell D, Glasziou P, Hill S. How to use the evidence: assessment and application of scientific evidence. Canberra: National Health and Medical Research Council, 2000.
3. Fox KA, Clayton TC, Damman P, et al; FIR Collaboration. Long-term outcome of a routine versus selective invasive strategy in patients with non-ST-segment elevation acute coronary syndrome: a meta-analysis of individual patient data. J Am Coll Cardiol 2010; 55: 2435-2445.
4. Steg PG, FitzGerald G, Fox KA. Risk stratification in non-ST-segment elevation acute coronary syndromes: troponin alone is not enough. Am J Med 2009; 122: 107-108.
5. Topol EJ; GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet 2001; 357: 1905-1914.

Online responses are no longer available. Please refer to our instructions for authors page for more information.